linjc16/ctgov huggingface dataset:
Biomarker-based Algorithm for Diagnosis of Glioma

Study Overview
=================
Brief Summary
-----------------
ATRX (X-linked mental retardation and alpha-thalassaemia syndrome protein) loss and pTERT (Telomerase reverse transcriptase) mutation are diagnostic markers of gliomas. However, 4 to 28% of gliomas shows none of these alterations. The aim of this project is to propose a new test able to detect the telomeric status for every glioma. Based on this test and other markers (such as mutation of IDH1 (isocitrate dehydrogenase 1) and IDH2 (isocitrate dehydrogenase 2)), investigators propose an algorithm, able to classify the main subtypes of gliomas (astrocytoma, oligodendroglioma and glioblastoma).

Official Title
-----------------
Development of a New Algorithm-based Classification for Glioma

Conditions
-----------------
Glioma

Intervention / Treatment
-----------------
* Other: PCR (Polymerase Chain Reaction)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with a diagnosis of glioma (retrospective), Patient with available biological material : extracted DNA and/or FFPE tissue and/or frozen sample. Samples are not required any more for diagnosis purpose Patient with informed consent Exclusion Criteria: Patient with no informed consent Patients with no available biological sample

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Glioma<br>FFPE (Formalin-Fixed Paraffin-Embedded) or frozen samples will be used for DNA extraction. Different gliomas tumors will be used (oligodendroglioma, astrocytomas, glioblastoma) | Other: PCR (Polymerase Chain Reaction)<br>* Biological testing of FFPE (Formalin-Fixed Paraffin-Embedded) or frozen samples of tumors will be led. These tissues have been collected during the treatment of patients (for diagnostic purposes). A molecular analysis (polymerase chain reaction) is led on DNA extracted from FFPE/frozen conserved tissues, and a result is produced by the algorithm.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determination of the prognosis and diagnosis values of a new qPCR (quantitative polymerase chain reaction) -based biological testing in glioma | An algorithm will be built, based on the result of this specific biological testing combined with other markers (determined in routine clinical testing). The algorithm parameters will be set using samples with a clear diagnosis (concordant molecular and immuno-histological markers). Then gliomas with uncertain diagnosis will be classified and the global overall survival will be predicted. Biological testing will be performed during one year and the analyses in terms of disease outcome will be refreshed every year. | 1 year |
Exparel as a Nerve Block for Severe Hand Pain

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate whether the use of the study drug (Exparel) is safe and effective for treating circulation problems and pain in the hand or fingers.

Official Title
-----------------
Chemical Sympathectomy Following Peripheral Nerve Block With Liposomal Bupivacaine

Conditions
-----------------
CREST Syndrome, Peripheral Vascular Disease, Raynaud Disease, Scleroderma, Diffuse

Intervention / Treatment
-----------------
* Drug: liposomal bupivacaine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Society of Anesthesiologists (ASA) status I-IV Exclusion Criteria: True Allergy, not sensitivity to: local anesthetics, midazolam, fentanyl, propofol, ketamine Previous surgery or significant trauma involving the radial or ulnar arteries (previous history of angiography and intravascular catheter placement are permitted) Pregnancy Severe hepatic impairment Evidence of infection at or near the proposed needle insertion site Any sensorimotor deficit of the ipsilateral upper extremity, whether acute or chronic as determined by the PI and/or designee

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Exparel<br>20 mL liposomal bupivacaine injected once | Drug: liposomal bupivacaine<br>* injected as an axillary block<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| radial and ulnar arterial blood flow |  | 1 hour | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain measured by Visual analog scale. |  | 1 month |
TC-WYRE: TAXUS Express Stent vs. Cypher Stent - What's Your Real Life Experience?

Study Overview
=================
Brief Summary
-----------------
To compare the relative efficacy and safety of the TAXUS Express2 stents and the Cypher stents among a broad, unselected patient population treated in a nationwide, multi-center clinical registry representative of 'real-world,' contemporary clinical practice. A secondary objective is to examine performance of the two stents in pre-specified subgroup populations and examine regional and national patterns in outcomes.

Official Title
-----------------
TC-WYRE: TAXUS Express Stent vs. Cypher Stent - What's Your Real Life Experience?

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Device: TAXUS Stent and Cypher Stent


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients treated with a TAXUS Express2 stent or a Cypher stent between April 1, 2005 and June 30, 2005. Exclusion Criteria: Simultaneous treatment with both TAXUS and Cypher stents during the index revascularization. Patients who have undergone previous target vessel(s), stenting procedure within 9 months of the index procedure will be excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: TAXUS Stent and Cypher Stent|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Epidemiology and Outcome of Anaphylactic Shocks Admitted to Intensive Care Unit

Study Overview
=================
Brief Summary
-----------------
Anaphylaxis is a severe life-threatening reaction following exposure to an antigen. Its incidence is progressively increasing in the general population over years, accompanied with an increased number of hospitalizations. Although rare, this condition is often associated with a significant morbidity and mortality. The mortality rate has been recently estimated at 0.84 (95% CI, 0.79 to 0.88) per million per year in the French adult population. Age, chronic medication and cardiac or pulmonary comorbidities have been reported to increase the risk of a severe reaction. Obesity, age and cardiovascular comorbidities have been identified as risk factors for fatal anaphylaxis. However, the risk factors for death after ICU admission have not been elucidated yet.

Official Title
-----------------
Epidemiology and Outcome of Anaphylactic Shocks Admitted to Intensive Care Unit: a French Retrospective Multicenter Study

Conditions
-----------------
Anaphylaxis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Being > 18 years old suffered an anaphylactic reaction, regardless of the location or causative allergen transferred alive in an ICU Exclusion Criteria: dead within less than one hour after admission

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| In-ICU mortality | The number of participants deceased within ICU hospitalisation | Day 30 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Volume of fluid administered | The volume of fluid administered during priori to and during ICU stay, in millilitres will be noted | Day 30 | 
| Amount of epinephrine | Quantity of epinephrine administered during ICU stay | Day 30 | 
| Amount of norepinephrine | Quantity of norepinephrine administered during ICU stay | Day 30 | 
| Number and severity of organ failure | The severity of organ failure will be assessed with the SOFA score | Day 30 | 
| Extracorporeal life support requirement | The number of participants that required ECMO V/V or A/V | Day 30 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fluid management, mortality